10:26 AM
 | 
Nov 09, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Bone stops Phase III of Preob cells in osteonecrosis for futility

Bone Therapeutics S.A. (Euronext:BOTHE) discontinued a Phase III trial of its Preob cells to treat osteonecrosis of the hip after an interim 12-month analysis by a DSMB showed that the trial was unlikely to meet its primary endpoint at the...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >